Binding differentiation inhibitor 1 (ID-1) in breast cancer among female athletes, utilizing smart medicine approaches. By establishing a breast cancer cell line experiment, we assessed the expression of ID-1 in breast cancer tissues and adjacent normal tissues, compared ID-1 expression levels across different breast cancer cell groups, investigated the impact of ID-1 on Src kinase activation in breast cancer cells, and explored the relationship between ID-1 expression and clinical factors relevant to female athletes. Results: The investigation revealed a significantly higher positive expression rate of ID-1 in breast cancer tissues compared to adjacent non-cancerous tissues (P<0.05). The shRNA-ID-1 group exhibited a notable decrease in ID-1 mRNA and protein expression levels compared to the Control group and the shRNA-NC group (P<0.05), indicating effective ID-1 silencing. Conversely, the PCDNA3.1-ID-1 group showed a significant increase in ID-1 mRNA and protein expression compared to the Control group and PCDNA3.1-NC group (P<0.05), suggesting enhanced ID-1 expression. Additionally, the expression level of phosphorylated Src (p-Src) protein in SUM159 cells was significantly reduced in the shRNA-ID-1 group compared to Control and shRNA-NC groups (P<0.05), while it was significantly increased in the PCDNA3.1-ID-1 group compared to Control and PCDNA3.1-NC groups (P<0.05). Importantly, ID-1 expression was significantly correlated with tumor stage in female athletes (P<0.05). Conclusion: ID-1 plays a pivotal role in enhancing the stem cell characteristics of breast cancer cells and promoting angiogenesis within breast cancer, potentially through the activation of the Src kinase pathway. The findings suggest that ID-1 could be a critical factor in the development and progression of breast cancer in female athletes, underlining the importance of smart medicine in identifying and targeting molecular pathways for effective breast cancer treatment and prevention.